University of Minnesota, Medical School - Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine American Board of Internal Medicine Sub-certificate in Infectious Disease (Internal Medicine)
License Records
David M Markovitz
Address:
1415 Wl St, Ann Arbor, MI
Phone:
(734)6471786
License #:
2469 - Expired
Category:
Health Care
Issued Date:
Dec 9, 2014
Effective Date:
Dec 13, 2016
Expiration Date:
Dec 8, 2016
Type:
Medical Doctor Expert Witness Certificate
Us Patents
Compositions And Methods For Detecting Cancer And For Inhibiting Metastasis
David M. Markovitz - Ann Arbor MI, US Nirit Mor-Vaknin - Ann Arbor MI, US Evan T. Keller - Ann Arbor MI, US Christopher L. Hall - Ypsilanti MI, US Susan M. Hiniker - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 39/395
US Classification:
4241301, 5303871
Abstract:
The present invention relates to compositions and methods for detecting cancer (e. g. , prostate cancer) and for inhibiting metastasis (e. g. , associated with prostate cancer). In particular, the present invention provides methods of detecting vimentin expression and secretion and for characterizing cancer (e. g. , prostate cancer). In addition, the present invention provides methods for inhibiting metastasis (e. g. , of prostate cancer) via altering (e. g. , inhibiting) vimentin expression and/or activity.
Methods Of Secretory Vimentin Detection And Modulation
David M. Markovitz - Ann Arbor MI, US Nirit Mor-Vaknin - Ann Arbor MI, US Antonello Punturieri - Ann Arbor MI, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
G01N 33/53
US Classification:
435 71, 435 72, 435 732, 435325, 436501, 4241301
Abstract:
The present invention relates to methods for screening and modulating the bioavailability of extracellular secretory vimentin. In particular, the present invention provides inhibitors and activators of secretory vimentin including antibodies, small interfering RNAs, and antisense oligonucleotides. The present invention thus provides novel drug targets for enhanced anti-microbial response, and methods of using such modulators to beneficially alter the pathophysiologic effects of secretory vimentin.
Methods Of Inhibiting Host-Cell Mediated Viral Replication
David Markovitz - Ann Arbor MI, US Neil Faulkner - Ypsilanti MI, US Brian Lane - Ann Arbor MI, US
International Classification:
A61K048/00 A61K031/35
US Classification:
514/044000, 514/454000
Abstract:
Methods are provided for inhibiting or suppressing viral replication in an infected host cell. More specifically, methods are provided for inhibiting or suppressing viral replication in an infected host cell by administering compounds that inhibit cellular protein phosphatase 2A. Such methods are advantageous for treating viral infections such human immunodefeciency virus infections.
David Markovitz - Ann Arbor MI, US Brian Lane - Ann Arbor MI, US Peter Polverini - Falcon Heights MN, US Robert Strieter - Sherman Oaks CA, US
International Classification:
A61K039/395 A61K038/17
US Classification:
424/144100, 514/002000
Abstract:
Methods are provided for inhibiting or suppressing viral replication in an infected host cell. More specifically, methods are provided for inhibiting or suppressing viral replication in an infected host cell by administering compounds that interfere with the binding of C-X-C chemokines to C-X-C chemokine receptors. Such methods are advantageous for treating viral infections such as human immunodefeciency virus infections.
David Markovitz - Ann Arbor MI, US Mark H. Kaplan - Ann Arbor MI, US Michael H. Dosik - Setauket NY, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
C12Q 1/68 G01N 33/574 C12Q 1/02
US Classification:
435 6, 435 723, 435 29
Abstract:
The present invention relates to compositions and methods for cancer diagnosis and therapy, including but not limited to, cancer markers. In particular, the present invention relates to HERV-K(HML-2) target titers as diagnostic markers, and HERV-K(HML-2) therapeutic targets for HIV-related cancers, and other cancers.
Dek Protein Compositions And Methods Of Using The Same
David A. Markovitz - Ann Arbor MI, US Nirit Mor-Vaknin - Ann Arbor MI, US Michael Khodadoust - Ann Arbor MI, US Barbara S. Adams - Ann Arbor MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:
A61K 39/395 A61K 31/7105 C12Q 1/68 G01N 33/535
US Classification:
4241411, 514 44, 4241301, 435 6, 435 792
Abstract:
The present invention relates to DEK protein compositions (e.g., antibodies, small molecule inhibitors, siRNAs) and methods of using the same. In particular, the present invention provides compositions and methods for treating autoimmune disease (e.g., juvenile rheumatoid arthritis, lupus, etc.) and for inhibiting inflammation (e.g., associated with autoimmune disease) and cellular chemotaxis (e.g., of neutrophils, NK cells and T cells). The present invention further provides a diagnostic marker (e.g., DEK antigen) for autoimmune disease.
Compositions and methods to treat lymphoma and cancer are disclosed. In particular, the method teaches treatment of lymphoma and cancer using anti-HERV-K(HML-2) therapies. Further taught are compositions and methods for characterizing patient samples to, for example, select or identify therapeutic options or assess the impact of therapies.
The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and re-search use. In particular, the present invention provides antiviral and antimicrobial lectin compounds (BanLec) isolated from bananas. These compounds have low mitogenicity and pro-inflammatory activity whilst maintaining anti-HIV-1 activity.